文献速递肾小球疾病急性肾损伤

风险分层预测抗肾小球基底膜病的肾脏生存

Risk Stratification to Predict Renal Survival in Anti-Glomerular Basement Membrane Disease.
PubMed 文献 · J Am Soc Nephrol · 2022-11-29

该回顾性多中心国际队列纳入174例抗肾小球基底膜病患者,验证ANCA相关血管炎肾脏风险评分可迁移至抗GBM病,诊断时需肾脏替代治疗与活检正常肾小球百分比为独立预测因子,按二者分层可改善肾脏生存预测,可能有助于疾病管理。

要点

  • 肾脏风险评分可迁移至抗GBM病,低、中、高危组36个月肾脏生存分别为100%、62.4%、20.7%。
  • 诊断时需RRT与活检正常肾小球百分比是ESKD独立预测因子。
  • 按RRT与正常肾小球10%分四组,36个月肾脏生存96.4%至14.1%。

核心结论

  • 肾脏风险评分概念可迁移至抗GBM病,按诊断时需RRT与肾脏组织学分層可改善预测,突显正常肾小球的重要性,此种分层可能有助于抗GBM病的管理。

研究设计与样本

  • 回顾性、多中心、国际队列研究,最终分析纳入174例患者(来自总共191例)。

主要发现

  • 肾脏风险评分是ESKD的强预测因子,低危、中危、高危组36个月肾脏生存分别为100%、62.4%、20.7%。
  • 诊断时需RRT与活检正常肾小球百分比是ESKD的独立预测因子。
  • 肾脏恢复的最佳预测因子为正常肾小球百分比,切点10%正常肾小球可提供良好分层。
  • 包含RRT与正常肾小球(N)预测因子的模型在肾脏生存显著差异方面获得更优判别。
  • 四组36个月肾脏生存分别为:无RRT且N≥10%组96.4%、无RRT且N<10%组74.0%、需RRT且N≥10%组42.3%、需RRT且N<10%组14.1%。

关键数值与推荐

  • 肾脏风险评分低危组36个月肾脏生存100%,中危组62.4%,高危组20.7%。
  • 正常肾小球百分比切点10%用于分层。
  • 四风险组36个月肾脏生存:无RRT且N≥10%为96.4%,无RRT且N<10%为74.0%,需RRT且N≥10%为42.3%,需RRT且N<10%为14.1%。

临床怎么用

  • 作者认为按诊断时需RRT与肾脏组织学分層可改善预测,此种分层可能有助于抗GBM病的管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

SIGNIFICANCE STATEMENT: Most patients with anti-glomerular basement membrane (GBM) disease present with rapidly progressive glomerulonephritis, and more than half develop ESKD. Currently, no tools are available to aid in the prognostication or management of this rare disease. In one of the largest assembled cohorts of patients with anti-GBM disease (with 174 patients included in the final analysis), the authors demonstrated that the renal risk score for ANCA-associated vasculitis is transferable to anti-GBM disease and the renal histology is strongly predictive of renal survival and recovery. Stratifying patients according to the percentage of normal glomeruli in the kidney biopsy and the need for RRT at the time of diagnosis improves outcome prediction. Such stratification may assist in the management of anti-GBM disease. BACKGROUND: Prospective randomized trials investigating treatments and outcomes in anti-glomerular basement membrane (anti-GBM) disease are sparse, and validated tools to aid prognostication or management are lacking. METHODS: In a retrospective, multicenter, international cohort study, we investigated clinical and histologic parameters predicting kidney outcome and sought to identify patients who benefit from rescue immunosuppressive therapy. We also explored applying the concept of the renal risk score (RRS), currently used to predict renal outcomes in ANCA-associated vasculitis, to anti-GBM disease. RESULTS: The final analysis included 174 patients (out of a total of 191). Using Cox and Kaplan-Meier methods, we found that the RRS was a strong predictor for ESKD. The 36-month renal survival was 100%, 62.4%, and 20.7% in the low-risk, moderate-risk, and high-risk groups, respectively. The need for renal replacement therapy (RRT) at diagnosis and the percentage of normal glomeruli in the biopsy were independent predictors of ESKD. The best predictor for renal recovery was the percentage of normal glomeruli, with a cut point of 10% normal glomeruli providing good stratification. A model with the predictors RRT and normal glomeruli ( N ) achieved superior discrimination for significant differences in renal survival. Dividing patients into four risk groups led to a 36-month renal survival of 96.4% (no RRT, N ≥10%), 74.0% (no RRT, N <10%), 42.3% (RRT, N ≥10%), and 14.1% (RRT, N <10%), respectively. CONCLUSIONS: These findings demonstrate that the RRS concept is transferrable to anti-GBM disease. Stratifying patients according to the need for RRT at diagnosis and renal histology improves prediction, highlighting the importance of normal glomeruli. Such stratification may assist in the management of anti-GBM disease. PODCAST: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/JASN/2023_02_27_JASN0000000000000060.mp3.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Floyd L, Bate S, Hadi Kafagi A, et al. Risk Stratification to Predict Renal Survival in Anti-Glomerular Basement Membrane Disease. J Am Soc Nephrol. 2022. PMID: 36446430. doi:10.1681/ASN.2022050581

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。